On Invalid Date, Neuropace (NASDAQ: NPCE) reported Q1 2024 earnings per share (EPS) of -$0.32, up 21.95% year over year. Total Neuropace earnings for the quarter were -$8.93 million. In the same quarter last year, Neuropace's earnings per share (EPS) was -$0.41.
As of Q2 2024, Neuropace's earnings has grown year over year. Neuropace's earnings in the past year totalled -$31.51 million.
What was NPCE's revenue last quarter?
On Invalid Date, Neuropace (NASDAQ: NPCE) reported Q1 2024 revenue of $18.12 million up 25.23% year over year. In the same quarter last year, Neuropace's revenue was $14.47 million.
What was NPCE's revenue growth in the past year?
As of Q2 2024, Neuropace's revenue has grown 42.07% year over year. This is 31.38 percentage points higher than the US Medical Devices industry revenue growth rate of 10.69%. Neuropace's revenue in the past year totalled $69.07 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.